Larvol Delta - Caribou-Biosciences-Announces-Dosing-of-First-Patient-in-the-CaMMouflage-Phase-1-Trial-of-CB011-an-Allogeneic-AntiBCMA-CART-Cell-Therapy-for-the-Treatment-of-Relapsed-or-Refractory-Multiple-Myeloma

CB-011 - Caribou Biosci

https://www.globenewswire.com/news-release/2023/03/29/2636615/0/en/Caribou-Biosciences-Announces-Dosing-of-First-Patient-in-the-CaMMouflage-Phase-1-Trial-of-CB-011-an-Allogeneic-Anti-BCMA-CAR-T-Cell-Therapy-for-the-Treatment-of-Relapsed-or-Refract.html

Mar 29, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next